Table 2. Summary of therapeutic efficacy for docetaxel combined thlidomide vs. docetaxel alone in AIPC.
| Study | Regimen | Age(years) | Median OS (months) | Median PFS (months) | ≥50%PSA decline (Number) | Hematologic toxicities | Non-hematologic toxicities | ||
|---|---|---|---|---|---|---|---|---|---|
| Grade1–2 | Grade 3–5 | Grade1–2 | Grade 3–5 | ||||||
| Sissung TM 2008 | docetaxel plus thalidomide | N/A | N/A | N/A | N/A | N/A | 4(5%) | N/A | 1(1%) |
| docetaxel | N/A | N/A | N/A | ||||||
| Dahut WL 2004 | docetaxel plus thalidomide | 71(52–83) | 28.9 | 5.9 | 25/47 | 4(8%) | 7(14%) | 22(88%) | 9(18%) |
| docetaxel | 67(43–82) | 14.7 | 3.7 | 9/24 | 4(16%) | 7(28%) | 41(84%) | 2(8%) | |
| Figg WD 2001 | docetaxel plus thalidomide | 69(49–80) | N/A | N/A | 19/36 | N/A | 5(7%) | N/A | 1(1%) |
| docetaxel | N/A | N/A | 6/17 | ||||||
Abbreviation: OS: Overall survival; PFS: Progression-free survival; N/A: not applicable.